[1]CurrentPatentAssignee:CHINAPHARMACEUTICALUNIVERSITY-CN107296794,2017,ALocationinpatent:Paragraph0113-0115
Title: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Journal: The Cochrane database of systematic reviews 20121017
Title: Systematic review of medical therapy to prevent recurrent diverticulitis.
Journal: International journal of colorectal disease 20120901
Title: Protein-losing enteropathy in ulcerative colitis.
Journal: Case reports in gastroenterology 20120101
Title: A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease.
Journal: Archives of medical science : AMS 20111231
Title: Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database.
Journal: Digestive diseases and sciences 20111201
Title: Probiotics in inflammatory bowel diseases and associated conditions.
Journal: Nutrients 20110201
Title: Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.
Journal: Drug design, development and therapy 20110101
Title: An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease.
Journal: BMC gastroenterology 20110101
Title: Eosinophilic enteritis confined to an ileostomy site.
Journal: Case reports in gastroenterology 20110101
Title: Identification and characterisation of an iron-responsive candidate probiotic.
Journal: PloS one 20110101
Title: Activation of nitrofurazone by azoreductases: multiple activities in one enzyme.
Journal: Scientific reports 20110101
Title: Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
Journal: The American journal of gastroenterology 20101001
Title: Unilateral balsalazide-induced eosinophilic pneumonia in an ulcerative colitis patient.
Journal: The journal of the Royal College of Physicians of Edinburgh 20100901
Title: Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases.
Journal: Protein & cell 20100801
Title: A novel mechanism for azoreduction.
Journal: Journal of molecular biology 20100702
Title: PPARs in Irradiation-Induced Gastrointestinal Toxicity.
Journal: PPAR research 20100101
Title: Role of tyrosine 131 in the active site of paAzoR1, an azoreductase with specificity for the inflammatory bowel disease prodrug balsalazide.
Journal: Acta crystallographica. Section F, Structural biology and crystallization communications 20100101
Title: Dietary phenethylisothiocyanate attenuates bowel inflammation in mice.
Journal: BMC chemical biology 20100101
Title: Balsalazide in treating colonic diseases.
Journal: Expert opinion on drug metabolism & toxicology 20091201
Title: Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.
Journal: Journal of pediatric gastroenterology and nutrition 20091101
Title: Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study.
Journal: Digestive diseases and sciences 20091101
Title: Treatment options for uncomplicated diverticular disease of the colon.
Journal: Journal of clinical gastroenterology 20091001
Title: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.
Journal: Expert opinion on drug metabolism & toxicology 20091001
Title: Adalimumab for the treatment of fistulas in patients with Crohn's disease.
Journal: Gut 20090701
Title: Balsalazine decreases intestinal mucosal permeability of dextran sulfate sodium-induced colitis in mice.
Journal: Acta pharmacologica Sinica 20090701
Title: A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.
Journal: Digestive diseases and sciences 20090601
Title: Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Journal: The American journal of gastroenterology 20090601
Title: Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.
Journal: Digestive diseases and sciences 20090401
Title: [Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis].
Journal: Orvosi hetilap 20090301
Title: [Effect of balsalazide on intestinal mucosal permeability of dextran sulfate sodium-induced colitis in mice].
Journal: Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20090301
Title: Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Journal: Gut 20090201
Title: Granulomatous pigmented purpura: an unusual histological variant.
Journal: The American Journal of dermatopathology 20090201
Title: Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation.
Journal: PloS one 20090101
Title: IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein.
Journal: PloS one 20090101
Title: Isolation of Mycobacterium avium subspecies paratuberculosis reactive CD4 T cells from intestinal biopsies of Crohn's disease patients.
Journal: PloS one 20090101
Title: Drugs associated with more suicidal ideations are also associated with more suicide attempts.
Journal: PloS one 20090101
Title: Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease.
Journal: Clinical and experimental gastroenterology 20090101
Title: Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.
Journal: Clinical and experimental gastroenterology 20090101
Title: Balsalazide-induced myocarditis.
Journal: International journal of cardiology 20081128
Title: Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.
Journal: Journal of clinical gastroenterology 20080901
Title: Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
Journal: Gut 20080701
Title: Balsalazide disodium for the treatment of ulcerative colitis.
Journal: Expert review of gastroenterology & hepatology 20080401
Title: Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis.
Journal: Reproductive toxicology (Elmsford, N.Y.) 20080201
Title: Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?
Journal: Pharmacological research 20080101
Title: Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial.
Journal: Patient preference and adherence 20080101
Title: The role of mesalamine in the treatment of ulcerative colitis.
Journal: Therapeutics and clinical risk management 20071001
Title: Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis.
Journal: Therapeutics and clinical risk management 20071001
Title: Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon.
Journal: International journal of colorectal disease 20070901
Title: Effect of sulphasalazine and balsalazide on histamine release from mast cells.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20070401
Title: Pyostomatitis vegetans: A clinical marker of silent ulcerative colitis.
Journal: Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20070201
Title: On the action of 5-amino-salicylic acid and sulfapyridine on M. avium including subspecies paratuberculosis.
Journal: PloS one 20070101
Title: Ulcerative colitis treatment for children and teens.
Journal: FDA consumer 20070101
Title: Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation.
Journal: Trials 20070101
Title: Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
Journal: Alimentary pharmacology & therapeutics 20061001
Title: A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis.
Journal: Managed care interface 20061001
Title: Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20060901
Title: Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Journal: Reviews in gastroenterological disorders 20060101
Title: A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
Journal: PloS one 20060101
Title: Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients.
Journal: International journal of radiation oncology, biology, physics 20051201
Title: 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
Journal: Gut 20051101
Title: Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide.
Journal: Gastroenterology 20050801
Title: Colonic targeting of aminosalicylates for the treatment of ulcerative colitis.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20050601
Title: Prediction of genotoxicity of chemical compounds by statistical learning methods.
Journal: Chemical research in toxicology 20050601
Title: Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
Journal: Inflammatory bowel diseases 20050301
Title: Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
Journal: Advanced drug delivery reviews 20050106
Title: Mesalamine delivery systems: do they really make much difference?
Journal: Advanced drug delivery reviews 20050106
Title: Safety of balsalazide therapy in the treatment of inflammatory bowel disease.
Journal: Reviews in gastroenterological disorders 20050101
Title: How important is onset of action in ulcerative colitis therapy?
Journal: Drugs 20050101
Title: Thyrotoxicosis co-existing with ulcerative colitis.
Journal: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20050101
Title: Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Journal: Medical science monitor : international medical journal of experimental and clinical research 20041101
Title: Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Journal: Alimentary pharmacology & therapeutics 20040515
Title: Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study.
Journal: Alimentary pharmacology & therapeutics 20040215
Title: Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Journal: Alimentary pharmacology & therapeutics 20040115
Title: The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
Journal: Reviews in gastroenterological disorders 20040101
Title: Review article: maintenance treatment of Crohn's disease.
Journal: Alimentary pharmacology & therapeutics 20030601
Title: Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt.
Journal: The American journal of gastroenterology 20030301
Title: The mesalamine wars heat up-enter balsalazide.
Journal: Gastroenterology 20030201
Title: Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Journal: Alimentary pharmacology & therapeutics 20030101
Title: Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis.
Journal: The American journal of gastroenterology 20030101
Title: Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer.
Journal: The American journal of gastroenterology 20030101
Title: The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria.
Journal: Inflammatory bowel diseases 20030101
Title: Balsalazide achieved symptomatic remission sooner than mesalamine for ulcerative colitis.
Journal: ACP journal club 20030101
Title: The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
Journal: Reviews in gastroenterological disorders 20030101
Title: Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Journal: The American journal of gastroenterology 20021201
Title: Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?
Journal: The American journal of gastroenterology 20020601
Title: A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Journal: The American journal of gastroenterology 20020601
Title: New developments in the treatment of inflammatory bowel disease.
Journal: Expert opinion on investigational drugs 20020301
Title: Balsalazide disodium.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020101
Title: A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
Journal: Alimentary pharmacology & therapeutics 20020101
Title: A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
Journal: Alimentary pharmacology & therapeutics 20020101
Title: Treatment of inflammatory bowel disease in the elderly: an update.
Journal: Drugs & aging 20020101
Title: Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Journal: Drugs 20020101
Title: New drugs 2002, part 1.
Journal: Nursing 20020101
Title: Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Journal: Scandinavian journal of gastroenterology. Supplement 20020101
Title: Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Journal: Gut 20011201
Title: Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.
Journal: Gut 20011101
Title: Review article: balsalazide therapy in ulcerative colitis.
Journal: Alimentary pharmacology & therapeutics 20011001
Title: Drug points: Hypersensitivity reaction to balsalazide.
Journal: BMJ (Clinical research ed.) 20010901
Title: Oral balsalazide (Colazal) for ulcerative colitis.
Journal: The Medical letter on drugs and therapeutics 20010723
Title: Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.
Journal: Gut 20010401
Title: Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61.
Title: Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789.
